任一文,周浩,陈伟杰,杜华安,张波,李丹,肖明阳,王子豪,凌智瑜,殷跃辉

• 1:重庆医科大学附属第二医院心血管内科
• 2:重庆医科大学附属第二医院心血管疾病神经调控研究治疗中心

摘要(Abstract)：

目的 比较肾动脉近段与全节段经皮去肾神经术（RDN）在高血压患者中的降压效果是否存在差异。方法 纳入2014年1月至2016年6月就诊于重庆医科大学附属第二医院的56例高血压患者，随机分为全节段消融组（25例）和近段消融组（31例）。收集所有患者术后6个月的24 h动态血压及术后12个月的诊室血压。结果 两组患者血压均有明显下降，但两组降压效应之间差异无统计学意义（P>0.05）。全节段消融组与近段消融组基线诊室血压分别为（180±15）/（104±10）mmHg与（180±12）/（103±8）mmHg，在术后12个月时分别降低为（142±9）/（82±7）mm Hg和（143±10）/（83±6）mm Hg，治疗前后两组内诊室收缩压与舒张压显著降低，差异均有统计学意义（均P<0.001）。两组基线24 h动态血压分别为（162±13）/（95±8）mm Hg与（160±12）/（94±8）mm Hg，而术后6个月时分别降低为（142±11）/（83±7）mm Hg和（141±8）/（81±7）mmHg，治疗前后两组内动态收缩压与舒张压亦显著降低，差异均有统计学意义（均P<0.001）。但两组间的诊室血压和动态血压的降幅差异均无统计学意义（均P>0.05）。未观察到与治疗相关的不良事件。结论 全节段消融与近段消融这两种术式的降压获益相似。

关键词(KeyWords)： 经皮去肾神经术;高血压;全节段消融;近段消融

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 任一文,周浩,陈伟杰,杜华安,张波,李丹,肖明阳,王子豪,凌智瑜,殷跃辉

参考文献(References)：

• [1] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1223-1249. DOI:10.1016/S0140-6736(20)30752-2.
• [2]中国高血压防治指南修订委员会，高血压联盟（中国，中华医学会心血管病学分会中国医师协会高血压专业委员会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
• [3] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281. DOI:10.1016/S0140-6736(09)60566-3.
• [4] Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(the Symplicity HTN-2 Trial):a randomised controlled trial[J].Lancet,2010,376(9756):1903-1909. DOI:10.1016/S0140-6736(10)62039-9.
• [5] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the Spyral HTNOn Med proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355. DOI:10.1016/S0140-6736(18)30951-6.
• [6] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(Spyral HTN-Off Med):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170. DOI:10.1016/S0140-6736(17)32281-X.
• [7] Azizi M,Sapoval M,Gosse P,et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension(DENERHTN):a multicentre,open-label,randomised controlled trial.Lancet[J]. Lancet,2015,385(9981):1957-1965. DOI:10.1016/S0140-6736(14)61942-5.
• [8] Mahfoud F,B?hm M,Schmieder R,et al. Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global Symplicity Registry[J]. Eur Heart J,2019,40(42):3474-3482. DOI:10.1093/eurheartj/ehz118.
• [9] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension(RADIOSOUND-HTN)[J]. Circulation,2019,139(5):590-600. DOI:10.1161/CIRCULATIONAHA.118.037654.
• [10] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401. DOI:10.1056/NEJMoa1402670.
• [11] Bhatt DL,Vaduganathan M,Kandzari DE,et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension:final follow-up of the randomised Symplicity HTN-3 Trial[J]. Lancet,2022,400(10361):1405-1416.DOI:10.1016/S0140-6736(22)01787-1.
• [12]李敏，范芳芳，张岩，等.肾交感神经消融术治疗高血压的有效性及安全性荟萃分析[J].中国介入心脏病学杂志，2021,29(7):391-402. DOI:10.3969/j.issn.1004-8812.2021.07.006.
• [13] Sakakura K,Ladich E,Cheng Q,et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man[J]. J Am Coll Cardiol,2014,64(7):635-643. DOI:10.1016/j.jacc.2014.03.059.
• [14] James PA,Oparil S,Carter BL,et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8)[J]. JAMA,2014,311(5):507-520. DOI:10.1001/jama.2013.284427.
• [15] García-Touchard A,Maranillo E,Mompeo B,et al. Microdissection of the human renal nervous system:implications for performing renal denervation procedures[J].Hypertension,2020,76(4):1240-1246. DOI:10.1161/HYPERTENSIONAHA.120.15106.
• [16] Sato Y,Kawakami R,Jinnouchi H,et al. Comprehensive assessment of human accessory renal artery periarterial renal sympathetic nerve distribution[J]. JACC Cardiovasc Interv,2021,14(3):304-315. DOI:10.1016/j.jcin.2020.09.043.
• [17] Liu H,Chen W,Lai Y,et al. Selective renal denervation guided by renal nerve stimulation in canine[J].Hypertension,2019,74(3):536-545. DOI:10.1161/HYPERTENSIONAHA.119.12680.
• [18]胡鑫渝，周浩，李丹，等.聚焦去肾交感神经术发展的关键——患者选择与精准消融[J].中国介入心脏病学杂志，2023,31(3):213-218. DOI:10.3969/j.issn.1004-8812.2023.03.008.
• [19] Qian PC,Barry MA,Lu J,et al. Transvascular pacing of aorticorenal ganglia provides a testable procedural endpoint for renal artery denervation[J]. JACC Cardiovasc Interv,2019,12(12):1109-1120. DOI:10.1016/j.jcin.2019.04.047.
• [20] Hori Y,Temma T,Wooten C,et al. Aorticorenal ganglion as a novel target for renal neuromodulation[J]. Heart Rhythm,2021,18(10):1745-1757. DOI:10.1016/j.hrthm.2021.06.1192.